In this phase 2b , open-label study with 14 treatment subgroups , 571 patients without cirrhosis who had not received treatment previously or who had not had a response to prior therapy were randomly assigned to a regimen of ABT-450 / r , combined with ABT-267 or ABT-333 or both , for 8 , 12 , or 24 weeks and received at least one dose of therapy .